Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2020 Publisher: Sanofi Pasteur Europe, 14 Espace Henry Vallée, 69007 Lyon, FRANCE Distributed in the UK by: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of anaphylaxis or other severe hypersensitivity reaction following administration of the vaccine.
Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to the needle injection. Procedures should be in place to prevent injury from faints and manage syncopal reactions.
DO NOT INJECT INTRAVASCULARLY.
Because intramuscular injection can cause injection site haematoma, STAMARIL should not be given by the intramuscular route to persons with any bleeding disorder, such as haemophilia or thrombocytopenia, or to persons on anticoagulant therapy. The subcutaneous route of administration should be used instead.
STAMARIL should be administered only to persons who are/will be at risk of infection with yellow fever virus or who must be vaccinated to comply with international health regulations. Before considering administration of yellow fever vaccine, care should be taken to identify those who might be at increased risk of adverse reactions following vaccination (see Section 4.3 and below).
Very rarely, YEL-AND has been reported following vaccination, with sequelae or with fatal outcome in some cases (see Section 4.8). To date most of cases of YEL-AND have been reported in primary vaccinees with an onset within 30 days of vaccination. The risk appears to be higher in those aged over 60 years and below 9 months of age (including infants exposed to vaccine through breastfeeding) although cases have been also reported in other age groups. Congenital or acquired immunodeficiency has also been recognized as a predisposing condition (see Section 4.3). However, cases of YEL-AND have also been reported in individuals with no identified risk factors. Vaccinees should be instructed to seek medical attention if they experience after vaccination any symptoms suggestive of YEL-AND such as high fever with headache or confusion, personality change or if they experience extreme tiredness, stiff neck, fits, loss of movement or feeling in part or all of the body, and they should also be reminded to inform their health care professional that they received yellow fever vaccine (see Section 4.8).
Very rarely, YEL-AVD resembling fulminant infection by wild-type virus has been reported following vaccination (see Section 4.8). The mortality rate has been around 60%. To date, most of cases of YEL-AVD have been reported in primary vaccinees with an onset within 10 days of vaccination. The risk appears to be higher in those aged over 60 years although cases have also been reported in other age groups. Thymectomy or history of thymus dysfunction have also been recognized as predisposing conditions (see Section 4.3). However, cases of YEL-AVD have also been reported in individuals with no identified risk factors. Vaccinees should be instructed to seek medical attention if they experience after vaccination any symptoms suggestive of a YEL-AVD such as pyrexia, myalgia, fatigue, headache or hypotension, as these can potentially progress quickly to liver dysfunction with jaundice, muscle cytolysis, thrombocytopenia, and acute respiratory and renal failure, and they should also be reminded to inform their health care professional that they received yellow fever vaccine (see Section 4.8).
STAMARIL must not be administered to immunosuppressed persons (see Section 4.3).
If the immunosuppression is temporary, vaccination should be delayed until the immune function has recovered. In patients who have received systemic corticosteroids for 14 days or more, it is advisable to delay vaccination until at least one month after completing the course.
STAMARIL must not be administrated to persons with symptomatic HIV infection or with asymptomatic HIV infection when accompanied by evidence of impaired immune function (see Section 4.3). However, there are insufficient data at present to determine the immunological parameters that might differentiate persons who could be safely vaccinated and who might mount a protective immune response from those in whom vaccination could be both hazardous and ineffective. Therefore, if an asymptomatic HIV-infected person cannot avoid travel to an endemic area available official guidance should be taken into account when considering the potential risks and benefits of vaccination.
Children aged at least 6 months (see Sections 4.2 and 4.3 and below) may be vaccinated if it is confirmed that they are not infected with HIV.
HIV infected children aged at least 6 months who are potentially in need of protection against yellow fever should be referred to a specialist paediatric team for advice on whether or not to vaccinate.
Children aged from 6 months up to 9 months should only be vaccinated under special circumstances (e.g. during major outbreaks) and on the basis of current official advice.
STAMARIL is contraindicated in children less than 6 months of age (see Section 4.3).
Persons aged 60 years and older may have an increased risk of serious and potentially fatal adverse reactions (including systemic and neurological reactions persisting more than 48 hours, YEL-AVD and YEL-AND) when compared to other age groups. Therefore, the vaccine should only be given to those who are visiting areas where there is an ongoing risk of yellow fever transmission at the time of travel. Countries designated by WHO as where vaccination is not generally recommended, or not recommended, should be considered as not representing a significant and unavoidable risk (refer to updated WHO list of countries with risk of yellow fever transmission) (see above and Section 4.8).
STAMARIL should not be used in pregnant and breast-feeding woman unless when clearly needed and following an assessment of the risks and benefits (see Section 4.6).
There are very few reports suggesting that transmission of Yellow Fever vaccine virus may occur from nursing mothers, who received Yellow Fever vaccine postpartum, to the infant. Following transmission the infants may develop YEL-AND from which the infants recover (see Section 4.6).
As with any vaccine, vaccination with STAMARIL may not protect 100% of vaccinated individuals.
The tip caps of the prefilled syringes contain a natural rubber latex derivative, which may cause allergic reactions in latex sensitive individuals.
STAMARIL contains less than 1 mmol sodium (23 mg) per dose that is to say essentially “sodium free”.
STAMARIL contains less than 1 mmol potassium (39 mg) per dose that is to say essentially “potassium free”.
STAMARIL contains approximately 8 mg of sorbitol (E420) per dose.
STAMARIL must not be mixed with any other vaccine or medicinal product in the same syringe.
If there is a need to administer another injectable vaccine(s) at the same time as STAMARIL each vaccine should be injected into a separate site (and preferably a separate limb).
This vaccine may be administered at the same time as measles vaccine if this is in accordance with official recommendations.
It may be administered at the same time as vaccines containing typhoid Vi capsular polysaccharide and/or inactivated hepatitis A virus.
It must not be administered to persons who are receiving immunosuppressive therapies such as high-dose systemic corticosteroids (e.g. daily dose of 20 mg or 2 mg/kg body weight of prednisone or equivalent for 2 weeks or more or daily dose of 40 mg or more of prednisone for more than one week), any other medicinal products including biologicals with known immunosuppressive properties, radiotherapy, cytotoxic drugs or any other condition which may result in immunocompromised status (see Section 4.3). If there is uncertainty about the level of immunosuppression, vaccination should be withheld and advice sought from a specialist.
It can induce false positive results with laboratory and/or diagnostic tests for other flavivirus related diseases such as dengue or Japanese encephalitis.
No animal developmental and reproductive studies have been conducted with STAMARIL and the potential risk for humans is unknown. Data on a limited number of exposed pregnancies indicate no adverse effects of STAMARIL on pregnancy or the health of the fetus/newborn child. Nevertheless, as STAMARIL is a live attenuated vaccine, it should not be given during pregnancy unless clearly needed and only after careful consideration of the potential risks and benefits. Pregnancy should be avoided for one month following vaccination.
As there is a probable risk of transmission of the vaccine virus strain to the infants from breastfeeding mothers, STAMARIL should not be given to nursing mothers unless when clearly needed such as during an outbreak and only if the potential benefits to the mother outweigh the potential risks, including those to the breastfed child (see Section 4.4.). In case vaccination is needed, it is recommended to interrupt breast-feeding for at least 2 weeks following vaccination.
No animal fertility studies have been conducted with STAMARIL and no fertility data are available in humans.
No studies on the effects on the ability to drive or use machines have been performed.
Cases of serious adverse events such as severe hypersensitivity or anaphylactic reactions, neurotropic or viscerotropic disease (YEL-AND; YEL-AVD) have been reported from post-marketing experience (see subsections b. Tabulated list of adverse reactions and c. Description of selected adverse reactions).
In all clinical studies, 4896 subjects (all ages) received STAMARIL.
In the most representative study in general population, the most frequently reported reactions (between 12% and 18% of subjects) were headache, asthenia, injection site pain and myalgia.
In the most representative study in toddler population, the most frequently reported reactions (between 32% and 35% of toddlers) were irritability, crying and appetite loss.
Adverse reactions usually occurred within the first three days following vaccination except pyrexia, which occurred between Day 4 and Day 14.
These reactions usually lasted for not more than 3 days.
Both local and systemic reactions were usually of mild intensity; however at least one severe injection site reaction was reported in 0.8% of subject in general population and in 0.3% of toddlers and at least one severe systemic reaction was reported in 1.4% of subjects in general population and 4.9% in toddlers.
The table below summarizes the frequencies of the adverse reactions that were recorded following vaccination with STAMARIL during clinical studies and worldwide post-marketing experience.
The adverse reactions are ranked under headings of frequency using the following convention: Very common (≥1/10), Common (≥1/100 to <1/10), Uncommon (≥1/1,000 to <1/100), Rare (≥1/10,000 to <1/1,000), Very rare (<1/10,000), Not known (cannot be estimated from available data).
Within each frequency grouping the adverse reactions are presented in the order of decreasing seriousness.
| System Organ Class | Frequency | Adverse reactions |
|---|---|---|
| Infections and infestations | Rare | Rhinitis |
| Very rare | YEL-AVD‡ | |
| Blood and lymphatic system disorders | Not known | Lymphadenopathy |
| Immune system disorders | Not known | Anaphylactoid reaction including angioedema |
| Metabolism and nutrition disorders | Very common | Appetite loss* |
| Nervous system disorders | Very common | Drowsiness*, Headache |
| Uncommon | Dizziness | |
| Very rare | YEL-AND‡, Seizure, Meningitis aseptic | |
| Not known | Paresthesia | |
| Gastrointestinal disorders | Very common | Vomiting† |
| Common | Nausea | |
| Uncommon | Abdominal pain | |
| Rare | Diarrhea | |
| Skin and subcutaneous tissue disorders | Common | Rash |
| Uncommon | Pruritus | |
| Not known | Urticaria | |
| Musculoskeletal and connective tissue disorders | Very common | Myalgia |
| Common | Arthralgia | |
| General disorders and administration site conditions | Very common | Irritability*, Crying*, Pyrexia†, Asthenia, Injection site pain/tenderness |
| Common | Injection site erythema/redness, Injection site hematoma, Injection site induration; Injection site oedema/swelling | |
| Uncommon | Injection site papule | |
| Not known | Influenza-like illness |
* Specific to paediatric population, (see Section d. Paediatric population)
‡ For clinical features see Section c. Description of selected adverse reactions
† Very common in toddlers (see Section d. Paediatric population), Common in general population
Cases of neurotropic disease (known as YEL-AND), some of which have had a fatal outcome, have been reported to occur within 30 days following vaccination with STAMARIL, and other yellow fever vaccines. YEL-AND may manifest as either encephalitis (with or without demyelination), or as a neurologic disease with peripheral nervous system involvement (e.g. Guillain-Barré syndrome). Encephalitis usually starts with high fever with headache that may progress to include encephalopathy (e.g. confusion, lethargy, personality change lasting more than 24 hours), focal neurologic deficits, cerebellar dysfunction or seizures. YEL-AND with peripheral nervous system involvement usually manifests as bilateral limb weakness or peripheral cranial nerve paresis with decreased or absent tendon reflexes (see Section 4.4).
Neurologic disease not meeting the criteria for YEL-AND has been reported. Manifestations may include cases of aseptic meningitis or seizure with no associated focal neurologic symptoms. Those cases are usually of mild or moderate severity and resolve spontaneously.
Cases of viscerotropic disease (known as YEL-AVD and formerly described as “Febrile Multiple Organ-System Failure”) have been reported following vaccination with STAMARIL, and other yellow fever vaccines, some of which have been fatal. In the majority of cases reported, the onset of signs and symptoms was within 10 days after the vaccination.
Initial signs and symptoms are non-specific and may include pyrexia, myalgia, fatigue, headache and hypotension, potentially progressing quickly to liver dysfunction with jaundice, muscle cytolysis, thrombocytopenia and acute respiratory and renal failure (see Section 4.4).
The safety of STAMARIL in paediatric population has been studied through a clinical study performed in 393 toddlers aged 12 to 13 months which received STAMARIL and placebo concomitantly.
The safety profile was assessed during the first 4 weeks following vaccination.
The following most frequently reported adverse reactions specific to the paediatric population were reported as “very common”: irritability (34.7%), appetite loss (33.7%), crying (32.1%) and drowsiness (22%).The other adverse reactions reported in toddlers were also reported from studies in general population:
Congenital or acquired immunodeficiency has been recognized as a potential risk factor for serious adverse events, including YEL-AND (See Sections 4.3 and 4.4).
Age of more than 60 years (see Section 4.4) has been recognized as a potential risk factor for YEL-AVD and YEL-AND.
Age below 9 months (including infants exposed to vaccine through breastfeeding) (see Section 4.4) has been recognized as a potential risk factor for YEL-AND.
Medical history of thymus dysfunction or thymectomy (see Sections 4.3 and 4.4) have been recognized as predisposing conditions for YEL-AVD.
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
In the absence of compatibility studies, this vaccine must not be mixed with other medicinal products.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
